Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate

Scandinavian Journal of Urology and Nephrology

Volumn 39, Issue 4, 2005, Pages 294-300

  Mikkola, Arto ^a   Aro, Jussi ^a   Rannikko, Sakari ^a   Oksanen, Hanna ^a   Ruutu, Mirja ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Cardiovascular complications; Parenteral estrogen; Progression; Prostatic cancer; Therapy

Indexed keywords

POLYESTRADIOL PHOSPHATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRAIN INFARCTION; CANCER GROWTH; CANCER STAGING; CANCER THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FOLLOW UP; HEART INFARCTION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CARDIOVASCULAR DISEASES; ESTRADIOL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORCHIECTOMY; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS;

EID: 27144552284     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/00365590510031228     Document Type: Article

References (31)

1. Cox RL, Crawford ED. Estrogens in the treatment of prostate cancer. J Urol 1995;154:1991-8.
2. Norlen BJ, Fritjofsson A, Gronquist L, Gunnarsson PO, Johansson SA, Plym-Forshell G. Plasma concentrations of estradiol and testosterone in single-drug polyestradiol phosphate therapy for prostatic cancer. Eur Urol 1987;13:193-7.
3. Stege R, Carlstrom K, Collste L, Eriksson A, Henriksson P, Pousette A. Single drug polyestradiol phosphate therapy in prostatic cancer. Am J Clin Oncol 1988;11(Suppl 2):S101-3.
4. Stege R, Carlstrom K, Collste L, Eriksson A, Henriksson P, Pousette A, et al. Single-drug parenteral estrogen treatment in prostatic cancer: a study of two maintenance-dose regimens. Prostate 1989;14:183-8.
5. Mikkola AK, Ruutu ML, Aro JL, Rannikko SA, Salo JO. Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group. Br J Urol 1998;82:63-8.
6. Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer-Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2002;36:405-13.
7. Mostofi FK. International histological classification of tumours, No. 22. Histological typing of prostate tumours. Geneva, Switzerland: WHO; 1980.
8. UICC TNM-classification of malignant tumours, Harmer MH, editor. 3rd edition, Geneva, Switzerland: 1978, Enlarged and revised 1982. p. 118-121.
9. Weimar C, Kraywinkel K, Rodl J, Hippe A, Harms L, Kloth A, et al. Etiology, duration, and prognosis of transient ischemic attacks: an analysis from the German Stroke Data Bank. Arch Neurol 2002;59:1584-8.
10. Donnelly R, Yeung JM. Management of intermittent claudication: the importance of secondary prevention. Eur J Vasc Endovasc Surg 2002;23:100-7.
11. Clark TG, Murphy MF, Rothwell PM. Long term risks of stroke, myocardial infarction, and vascular death in "low risk" patients with a non-recent transient ischaemic attack. J Neurol Neurosurg Psychiatry 2003;74:577-80.
12. Adams RJ, Chimowitz MI, Alpert JS, Awad IA, Cerqueria MD, Fayad P, et al. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Stroke 2003;34:2310-22.
13. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation 1997;96:44-9.
14. Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: scientific review. JAMA 2002;288:1388-95.
15. Wong M, Toh L, Wilson A, Rowley K, Karschimkus C, Prior D, et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum 2003;48:81-9.
16. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290:898-904.
17. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;324:71-86.
18. Gibbons RJ, Smith S, Antman E. American College of Cardiology. American Heart Association. American College of Cardiology/American Heart Association clinical practice guidelines. Part I: where do they come from? Circulation 2003;107:2979-86.
19. Alfthan O, Holsti LR. Prevention of gynecomastia by local roentgen irradiation in estrogen-treated prostatic carcinoma. Scand J Urol Nephrol 1969;3:183-7.
20. Iversen P. Carcinoma of the prostate. Response criteria. Scand J Urol Nephrol Suppl 1991;139:31-8.
21. Cox DR. Regression model of life tables. J R Stat Soc 1972;634:187-220.
22. Haapiainen R, Rannikko S, Alfthan O. Comparison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer. A 2-year follow-up report of a national, prospective cancer study. Br J Urol 1986;58:528-33.
23. Carlstrom K, Collste L, Eriksson A, Henriksson P, Pousette A, Stege R, et al. A comparison of androgen status in patients with prostatic cancer treated with oral and/or parenteral estrogens or by orchidectomy. Prostate 1989;14:177-82.
24. Henriksson P, Blomback M, Bratt G, Edhag O, Eriksson A, Vesterqvist O. Effects of oestrogen therapy and orchidectomy on coagulation and prostanoid synthesis in patients with prostatic cancer. Med Oncol Tumor Pharmacother 1989;6:219-25.
25. Aro J, Haapiainen R, Rasi V, Rannikko S, Alfthan O. The effect of parenteral estrogen versus orchiectomy on blood coagulation and fibrinolysis in prostatic cancer patients. Eur Urol 1990;17:161 5.
26. Henriksson P, Blomback M, Eriksson A, Stege R, Carlstrom K. Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma. Br Med J 1990;65:282-5.
27. Blajchman MA. An overview of the mechanism of action of antithrombin and its inherited deficiency states. Blood Coagul Fibrinolysis 1994;5(Suppl 1):S5-11.
28. Gathof BS, Picker SM, Rojo J. Epidemiology, etiology and diagnosis of venous thrombosis. Eur J Med Res 2004;30:95-103.
29. Kohli M, Kaushal V, Mehta P. Role of coagulation and fibrinolytic system in prostate cancer. Semin Thromb Hemost 2003;29:301-8.
30. Aro JL, Haapiainen RK, Rannikko SA, Alfthan OS. High dose polyoestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group. Br J Urol 1989;63:512-4.
31. Haapiainen R, Rannikko S, Alfthan O. Comparison of primary orchiectomy and polyoestradiol phosphate in the treatment of advanced prostatic cancer. Finnprostate Group. Br J Urol 1990;66:94-7.